{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-25-000091","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.242268+00:00","generated_at":"2026-05-16T22:18:48.644138+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AnaptysBio's rosnilimab fails Phase 2 UC trial; trial discontinued","bullets":["Rosnilimab did not meet primary (mMS change) or key secondary endpoints at Week 12 in moderate-to-severe UC.","Clinical remission 7% for both doses vs 5% and 4% endoscopic remission; placebo rates within historical ranges.","Trial discontinued saving at least $10M; update on rosnilimab in RA expected H1 2026 via strategic capital.","Reaffirms 2026 separation of biopharma from royalty assets; Jemperli royalties >$390M/yr at peak sales >$2.7B.","Expects ~$300M cash end-2025 including $75M milestone from GSK for Jemperli reaching $1B global net sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-25-000091","json":"https://secwatch.observer/filing/0001370053-25-000091.json","markdown":"https://secwatch.observer/filing/0001370053-25-000091.md","text":"https://secwatch.observer/filing/0001370053-25-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000091/0001370053-25-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000091/anab-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:18:48.644138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}